Article Figures & Data
Figures
- Figure 1.
Voriconazole Improves 12-Week Survival Compared With AmB Deoxycholate
AmB, amphotericin B; IA, invasive aspergillosis; VOR, voriconazole.
A, possible, probable, and proven IA; B, probable and proven IA; C, possible IA; D, possible, probable, and proven IA in allogenic hematopoietic stem cell transplant recipients.
Reprinted from Herbrecht R et al, Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis, 2015; Vol 60; Issue 5: Pages 713-720, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America.
- Figure 2.
Probability of IA Deaths by Treatment in Salvage Therapy Group
P = .11; n = 75.
IA, invasive aspergillosis.
Reprinted from Int J Antimicrob Agents, Vol 45, Raad II et al, Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies, Pages 283-288, Copyright 2014, with permission from Elsevier.
Tools
Table of contents
Cited By...
- No citing articles found.